Soligenix announced the halt of its Phase 3 FLASH2 trial for HyBryte™, a treatment for cutaneous T-cell lymphoma (CTCL), after an interim analysis showed the study did not meet efficacy expectations. Despite positive results in an earlier trial, the recent study showed no significant benefit after 18 weeks of treatment. The company will analyze the data to identify any patient subsets that might benefit and consider discussions with regulators. With $6 million cash and runway into Q2 2027, Soligenix will explore strategic options including mergers, acquisitions, and advancing other pipeline drugs like SGX945 for Behçet's Disease, which recently received orphan drug and promising medicine designations.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Immuron Limited announced a 6% increase in global sales for FY26, reaching AUD$7.7 million, driven by a 10% rise in Australian sales and significant growth in Canada and the US markets. The growth in Australia is attributed to enhanced digital market...
GRAVITY Co., Ltd. has officially launched Ragnarok: The New World, an open-world MMORPG based on the popular Ragnarok IP, in Southeast Asia on July 16, 2026. The game is available on both Mobile (Google Play and Apple App Store) and PC (official webs...
Zymeworks Inc. will release its second quarter 2026 financial results after market close on August 6, 2026. The company will not hold an earnings call following the release due to its pending acquisition of Theravance Biopharma. This acquisition will...
Global Net Lease, Inc. announced it will release its financial results for the second quarter ending June 30, 2026, on August 5 after the NYSE closes. The company will hold a conference call and webcast on August 6 at 11:00 a.m. ET to discuss the res...
